摘要
用超滤荧光极化免疫分析法测定血清地高辛游离浓度，结合其游离百分率，估算了１２位伴有肾功能不全的慢性心衰患者血清地高辛总浓度和地高辛样免疫活性物质（ＤＬＩＳ）浓度。结果表明，患者的血清实测地高辛游离浓度为０．７９±０．４８ｎｍｏｌ·Ｌ－１；实测地高辛总浓度为１．３１±０．８０ｎｍｏｌ·Ｌ－１，明显高于计算的地高辛总浓度（１．０５±０．６４ｎｍｏｌ·Ｌ－１），Ｐ＜０．０１。计算的ＤＬＩＳ浓度为０．２７±０．１９ｎｍｏｌ·Ｌ－１，该结果与用Ｄａｓｇｕｐｔａ等新近报道的计算方法获得的数据（０．２９±０．２２ｎｍｏｌ·Ｌ－１）一致（Ｐ＞０．０５）。
Measurement of serum digoxin concentration is recommended as a routine in patients undergoing digoxin therapy because its therapeutic range is narrow. The presence of a high concentration of digoxin like immunoreactive substances(DLIS) in human serum have been reported in a number of pathophysiological conditions. DLIS which cross react with anti digoxin antibodies, can falsely elevate the total digoxin concentration and is troublesome in the therapeutic monitoring of digoxin. The concentrations of serum total digoxin and DLIS in twelve patients of cardiac failure with renal insufficiency were estimated after determination of free digoxin by ultrafiltration with fluorescence polarization immumoassay. In these patients, the free digoxin concentration in serum determined was 0.79±0.48(0.46～2.10) nmol·L -1 . The total digoxin determined(1.31±0.80 nmol·L -1 ) was significantly higher than the calculated total digoxin(1.05±0.64 nmol·L -1 )( P < 0.01 ), suggesting the presence of elevated DLIS in serum for these patients. The calculated DLIS concentration was 0.27±0.19(0.07～0.76) nmol·L -1 . The results were well consistent with that obtained by recently published method of Dasgupta et al . In conclusion, the approach presented in this paper can estimate the true serum concentrations of digoxin and DLIS in patients of chronic cardiac failure with renal insufficiency.
出处
《药学学报》
CAS
CSCD
北大核心
1997年第3期174-177,共4页
Acta Pharmaceutica Sinica
